1 Abstract
An individual’s disease risk is affected by the populations that they belong to, due to shared genetics and shared environment. The study of fine-scale populations in clinical care will be important for reducing health disparities and for developing personalized treatments. In this work, we developed a novel health monitoring system, which leverages biobank data and electronic medical records from over 40,000 UCLA patients. Using identity by descent (IBD), we analyzed one type of fine-scale population, an IBD cluster. In total, we identified 376 IBD clusters, including clusters characterized by the presence of many significantly understudied communities, such as Lebanese Christians, Iranian Jews, Armenians, and Gujaratis. Our analyses identified thousands of novel associations between IBD clusters and clinical diagnoses, physician offices, utilization of specific medical specialties, pathogenic allele frequencies, and changes in diagnosis frequency over time. To enhance the impact of the research and engage the broader community, we provide a web portal to query our results: www.ibd.la
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
C.C. was supported by F31NS122538. C.C., N.Z., D.E., and E.P. were supported by grants from the NIH and DoD: R01CA227237, R01ES029929, R01MH122688, U01HG009080, R01HL155024, R01HL151152. R01GM142112, R01HG006399. N.Z., E.K., C.G., V.A., G.B. were supported by R01HG011345. A.C. was supported by T32HG002536 and DGE-1829071. V.A. was supported by DP5OD024579.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Patient Recruitment and Sample Collection for Precision Health Activities at UCLA is an approved study by the UCLA Institutional Review Board (UCLA IRB). IRB#17-001013
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Patient level EHR and genotyping data is protected due to patient privacy. Summary statistic data is available on www.ibd.la
